The Benefits of MammaPrint
The data, published in Nature and the New England Journal of Medicine, demonstrate that gene expression profiling is able to accurately predict the clinical outcome of breast cancer.
Key features of MammaPrint®
- Gene expression profiling is superior to current standards like the NIH, St. Gallen criteria and other nationally defined criteria for determination of the recurrence risk for breast cancer.
- Confidence: the genomic profile analysed with MammaPrint® is validated in more than 1000 patients and is backed by peer-reviewed medical research carried out to the highest standards and is extremely reproducible (Glas AM et al., Converting a breast cancer microarray signature into a high-throughput diagnostic test, BioMed Central Genomics 2006, vol 278, no 7, 30 October 2006, 2164-2167).
- A full service including provision of sampling kits, couriering of the sample, gene expression analysis and detailed communication of result.
- Accuracy: MammaPrint® is based on the expression analysis of multiple genes, quantified simultaneously, ensuring a higher degree of accuracy in determining the risk of breast cancer recurrence than currently available tests.
- Quality: MammaPrint® complies to the highest quality standards, our services are conducted under highly reproducible and state-of-the-art test conditions.
- FDA Approved.